

best assured of having their full effect if received by May 5, 1997.

Dated: March 26, 1997.

Martin K. Trusty,

Executive Officer, NIAAA.

[FR Doc. 97-8594 Filed 4-3-97; 8:45 am]

BILLING CODE 4140-01-M

Consensus Development Conference on Genetic Testing for Cystic Fibrosis

Notice is hereby given of the NIH Consensus Development Conference on "Genetic Testing for Cystic Fibrosis," which will be held April 14-16, 1997, in the Natcher Conference Center of the National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892. The conference begins at 8:30 a.m. on April 14, at 8:30 a.m. on April 15, and at 9:00 a.m. on April 16.

At the beginning of this decade, a test was developed which could identify individuals who carried the genetic mutation associated with cystic fibrosis. Concerned that this test might be inappropriately or prematurely used, a number of genetic and health professional organizations issued recommendations on its use. These groups considered the circumstances under which the tests should be offered and the populations that would potentially benefit. In almost every case, recommendations were made against using the test for large-scale population-based screening until more sensitive tests were developed and more had been learned about the risks and benefits of genetic testing for individuals and their families. Several statements called for additional support for research on the educational, laboratory, counseling, ethical, and cost/benefit issues associated with the delivery of population-based screening for cystic fibrosis. Since that time new research has yielded a large body of new data on these issues.

This conference will bring together the research investigators, health care providers, epidemiologists, geneticists, ethicists and other experts, as well as representatives of the public, to present and discuss the latest data.

After 1½ days of presentations and audience discussion, an independent, non-Federal consensus panel will weigh the scientific evidence and write a draft statement that it will present to the audience on the third day. The consensus statement will address the following key questions:

—What is the current state of knowledge regarding cystic fibrosis natural history, epidemiology, genotype-phenotype correlations, treatment,

and genetic testing in various populations?

- What has been learned about genetic testing for cystic fibrosis regarding (public and health professional) knowledge and attitudes, interest and demand, risks and benefits, effectiveness, cost, and impact?
- Should cystic fibrosis carrier testing be offered to: (1) individuals with a family history of cystic fibrosis; (2) adults in the preconception or prenatal period; and/or (3) the general population?
- What are the optimal practices for cystic fibrosis genetic testing (setting, timing, and the practices of education, consent, and counseling)?
- What should be the future directions for research relevant to genetic testing for cystic fibrosis and, more broadly, for research and public policy on genetic testing?

The primary sponsors of this meeting are the National Human Genome Research Institute and the NIH Office of Medical Applications Research. The conference is cosponsored by: the National Institute of Diabetes and Digestive and Kidney Diseases; the National Heart, Lung, and Blood Institute; the National Institute of Child Health and Human Development; the NIH Office of Rare Diseases; the National Institute of Mental Health; the National Institute of Nursing Research; the NIH Office of Research on Women's Health; the Agency for Health Care Policy Research; and the Centers for Disease Control and Prevention.

Advance information on the conference program and conference registration materials may be obtained from: Rose Salton, Technical Resources International, Inc., 3202 Tower Oaks Blvd., Suite 200, Rockville, Maryland 20852, (301) 770-3153, confdept@tech-res.com. The consensus statement will be submitted for publication in professional journals and other publications. In addition, the statement will be available beginning April 16, 1997 from the NIH Consensus Program Information Center, P.O. Box 2577, Kensington, Maryland 20891, phone 1-888-NIH-CONSENSUS (1-888-644-2667) and from the NIH Consensus Program site on the World Wide Web at <http://consensus.nih.gov>.

Dated: March 26, 1997.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 97-8593 Filed 4-3-97; 8:45 am]

BILLING CODE 4140-01-M

National Center for Research Resources; Notice of Meeting of the National Advisory Research Resources Council and its Planning Subcommittee

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Advisory Research Resources Council (NARRC), National Center for Research Resources (NCRR). This meeting will be open to the public as indicated below. Attendance by the public will be limited to space available.

This meeting will be closed to the public as indicated below in accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, for the review, discussion and evaluation of individual grant applications. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. Maureen Mylander, Public Affairs Officer, NCRR, National Institutes of Health, 1 Rockledge Center, Room 5146, 6705 Rockledge Drive, MSC 7965, Bethesda, Maryland 20892-7965, (301) 435-0888, will provide a summary of the meeting and a roster of the members upon request. Other information pertaining to the meeting can be obtained from the Executive Secretary indicated. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the Executive Secretary in advance of the meeting.

Name of Committee: The Subcommittee on Planning of the National Advisory Research Resources Council.

Place of Meeting: National Institutes of Health, 9000 Rockville Pike, Conference Room D, Natcher Building 45, Bethesda, Maryland 20892.

Open: May 22, 7:30 a.m.-8:45 a.m.

Purpose/Agenda: To discuss policy issues.

Name of Committee: National Advisory Research Resources Council.

Place of Meeting: National Institutes of Health, 9000 Rockville Pike, Conference Room E1 and E2, Natcher Building 45, Bethesda, Maryland 20892.

Open: May 22, 9 a.m. until recess.

Closed: May 23, 8:30 a.m. until 9:45 a.m.

Open: May 23, 10:00 a.m. until adjournment.

Purpose/Agenda: Report of Center Director and other issues related to Council business.

Executive Secretary: Louise Ramm, Ph.D., Deputy Director, National Center for Research Resources, Building 12A, Room